Bone News and Research

RSS

Exelixis reports interim data of XL184 for metastatic castration-resistant prostate cancer

Exelixis, Inc. today reported interim data from the cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with XL184 in an ongoing phase 2 adaptive randomized discontinuation trial (RDT).

18 Nov 2010

Exelixis reports interim data from phase 2 RDT trial for epithelial ovarian cancer

Exelixis, Inc. today reported interim data from the cohort of patients with advanced epithelial ovarian cancer, primary peritoneal, or fallopian tube carcinoma treated with XL184 in an ongoing phase 2 adaptive randomized discontinuation trial (RDT).

18 Nov 2010

States consider options for funding Medicaid

The Billings Gazette: Montana lawmakers questioned the state's top health official "about plans to hire a private company to manage part of Medicaid, asking why the administration hasn't had a more public discussion on the proposal." The Legislative Finance Committee also listened to "health care providers and former officials who experienced the state's 1995 foray into private management of Medicaid for the mentally ill — and how it became a disaster for its low-income patients and their providers."

18 Nov 2010

Titan Spine granted FDA clearance for Endoskeleton TO system

Titan Spine, a developer of novel interbody fusion implants, announced today that it has received FDA clearance to commercially release its Endoskeleton® TO system, which consists of a line of interbody devices placed through a Posterior Lumbar Interbody Fusion (PLIF) approach. The company plans to commercially release the product beginning in December, 2010.

18 Nov 2010

AACN endorses intraosseous vascular access

Recognizing that IV use is not always optimal to provide patients with fluids and medications, the American Association of Critical-Care Nurses (AACN) recently endorsed a consensus paper that recommends intraosseous (IO) vascular access in a variety of healthcare settings.

17 Nov 2010

Health professionals invited for 1st Asia-Pacific Osteoporosis Meeting

Healthcare providers in the Asia-Pacific region are coping with a rising tide of osteoporotic fractures. The IOF Regionals - 1st Asia- Pacific Osteoporosis Meeting, to take place in Singapore from December 10-13, 2010, is an ideal opportunity for health professionals in the region to acquire the latest practical information on osteoporosis and related fractures.

17 Nov 2010

Cardio3 BioSciences announces positive results from C-Cure Phase II clinical trial for heart failure

The Belgian biotechnology company, Cardio3 BioSciences a leader in discovery and development of regenerative and protective therapies for the treatment of cardiovascular diseases today announces positive six-month results, including significant functional and clinical benefit, from the Phase II clinical trial of its development programme C-Cure(R), designed as a novel stem cell therapy for heart failure based on breakthrough technology.

17 Nov 2010

Medtronic acquires Osteotech

Moving to expand its Biologics product offerings, Medtronic, Inc., announced today it has completed the acquisition of Osteotech, following payment of $6.50 per share in cash for each share of Osteotech stock, with a total transaction value of approximately $123 million.

16 Nov 2010

Misonix to introduce OsteoSculpt for facial bone surgery at EACMFS Congress

Misonix, Inc., a developer of state of the art, ultrasonic medical device technology, which worldwide is used for acute health conditions, has announced its attendance and exhibition at the 20th Congress of the European Association for Cranial-Maxillofacial Surgery (EACMFS), which was held recently in Bruges, Belgium.

16 Nov 2010

Merrion prepares Phase III study for Orazol in breast cancer treatment

After recent consultation with the FDA in November 2010, Merrion is preparing for its Phase III study for Orazol. If successful, the Phase III study will allow a new drug application for Orazol to be made under the FDA's abbreviated approval procedure section 505(b)(2) using a single Phase III study. The study will compare Orazol against placebo as an adjuvant breast cancer treatment with a primary endpoint of Disease Free Survival of patients with breast cancer.

16 Nov 2010

Research suggests targeting spleen may promote healing of spinal cord injury

The spleen, an organ that helps the body fight infections, might also be a source of the cells that end up doing more harm than good at the site of a spinal cord injury, new research suggests.

16 Nov 2010

GTx presents preclinical studies of GTx-758 and GTx-230 for treatment of cancer

GTx, Inc. announced the presentation of preclinical studies evaluating GTx-758, a selective estrogen receptor alpha agonist being developed for first line treatment of advanced prostate cancer, and GTx-230, a novel microtubule polymerization inhibitor.

15 Nov 2010

Bacterin third quarter revenue increases from $1.4 million to $4.2 million

Bacterin International Holdings, Inc., a developer of anti-infective coatings for medical applications and revolutionary bone graft material, today reported financial results for its third quarter ended September 30, 2010.

15 Nov 2010

Gadonanotubes effective for tracking stem cells: Study

Gadonanotubes (GNTs) developed at Rice University are beginning to show positive results in a study funded by a federal stimulus grant through the National Institutes of Health (NIH) last year.

15 Nov 2010

TU/e researchers image stages of calcification process in atherosclerosis

Atherosclerosis is characterized by hardening and thickening of artery walls, with serious health consequences. Researchers at Eindhoven University of Technology (TU/e) have imaged the stages in the calcification process at a nanometer scale.

15 Nov 2010

Vit D deficiency does not raise stroke risk in African-Americans

While vitamin D deficiency is associated with fatal stroke among whites, it is not linked to more stroke deaths among blacks, according to research presented at the American Heart Association's Scientific Sessions 2010.

15 Nov 2010

New mathematical model may help predict anemia risk

A collaboration between a physician-researcher at Massachusetts General Hospital (MGH) and a mathematician from Harvard University has led to development of a mathematical model reflecting how red blood cells change in size and hemoglobin content during their four-month lifespan.

15 Nov 2010

SANUWAVE third quarter revenues increase to $278,000

SANUWAVE Health, Inc., an emerging medical technology company focused on regenerative medicine, today reported financial results for the three and nine months ended September 30, 2010 and provided a business update.

12 Nov 2010

DOD-funded METRC consortium receives $38.6 million grant to improve care for wounded service members

One of two dozen major trauma centers named to be a part of the Department of Defense-funded Major Extremity Trauma Research Consortium (METRC), Saint Louis University will work to improve treatment for wounded service members and civilians. The partnership aims to conduct research to improve the care of major orthopaedic injuries sustained on the battlefield.

12 Nov 2010

Scientists unveil mechanism of liver regeneration

The liver's unique ability among organs to regenerate itself has been little understood. Now Weill Cornell Medical College scientists have shed light on how the liver restores itself by demonstrating that endothelial cells the cells that form the lining of blood vessels play a key role.

12 Nov 2010